PT Phapros, Tbk Reports Earnings Results for the Full Year Ended December 31, 2023
April 05, 2024
Share
PT Phapros, Tbk reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was IDR 1,014,129.71 million compared to IDR 1,168,474.43 million a year ago. Net income was IDR 5,959.33 million compared to IDR 28,069.87 million a year ago.
Basic earnings per share from continuing operations was IDR 7 compared to IDR 33 a year ago.
PT Phapros Tbk is an Indonesia-based pharmaceutical company. The Company's business pillars consist of branded/ethical prescription medicines: hospitals and pharmacies in addition to other healthcare institutions; over-the-counter drugs: pharmacies, retail; generic prescription drugs: government institutions and hospitals; toll-in manufacturing, and medical device. It offers medicines for cardiovascular and hematopoietic, gastrointestinal and hepatobiliary, hormone Genito, urinary endocrine and metabolic, vitamins and minerals nutrition, dermatology, local anesthesia, immune & allergy, and others. The Company's medical devices include ACS MB system, ACS FB and FB PS, Primary Hip Stem, INASHUNT Semilunar Flushing, BoneFill Ortho and NPC-STRIP G. Its branded drugs include Colkatriol 0.25 mcg 30 Cap, Diafac XR, Diafac 500 mg 10 tablets, Spirolactone 25 & 1, Dextamine Syrup 60 ml, Diapros Tablet, Proinfarction, anemone, Pladel, and others. The Company also operates calibration laboratory.
PT PHAPROS, TBK 
